ClinicalTrials.gg
TerminatedNCT04500665Updated Nov 18, 2026

Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

A Phase 2 interventional study of Colchicine and Placebo in Chronic Kidney Diseases, sponsored by Brigham and Women's Hospital. Terminated at 1 site in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Funding
Updated Nov 18, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital — 4 open to participants now, 5 under way, none of them phase 3. Renal Insufficiency, Chronic · Brigham and Women's Hospital.

Enrollment
14th of 14
4 · median 166
Started
2021
with 6 others
Phase 2
Only one
of the 21
Registered
8th of 21
by date

Among the 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is one of 7 that started in 2021, is the only one in phase 2, and was the 8th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Renal Insufficiency, Chronic by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.

03

Conditions studied

  • Chronic Kidney Diseases
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

A. Inclusion Criteria:

  • Age 21 years to 80 years (inclusive)
  • of 15 to 75 mL/min per 1.73 m2
  • Urine albumin-to-creatinine ratio of greater than 30 mg/g
  • Use of maximally tolerated doses of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker if urine albumin-to-creatinine ratio greater than 300 mg-g
  • Use of a sodium-glucose co-transporter-2 inhibitor if indicated in the opinion of the participant's primary clinician
  • Willing and able to provide written and to adhere to the study protocol

B. Exclusion Criteria:

  1. History of intolerance or allergy to colchicine
  2. Hospitalization for any reason within the previous 30 days
  3. Acute condition that requires emergent treatment in the opinion of a physician investigator
  4. Stage C or D heart failure according to ACC-AHA criteria77
  5. less than 40%
  6. Symptomatic valvular heart disease
  7. Congenital heart disease (corrected or uncorrected)
  8. History of orthotopic heart transplant
  9. Kidney failure, defined as kidney transplant recipient or requirement for hemodialysis or peritoneal dialysis
  10. Worsening kidney function or acute kidney injury, defined as an increase in serum creatinine of greater than 0.3 mg/dL in the previous 30 days or 50% within the previous 7 days
  11. Use of or anti-inflammatory medications within the previous 30 days, with the exception of less than 5 days of non-steroidal anti-inflammatory drugs or for acute pain or other acute conditions that have since fully resolved provided that the last dose of non-steroid anti-inflammatory drug was at least 7 days before enrollment
  12. Familial Mediterranean Fever, gout (unless no flare within the previous 12 months), pericarditis or other indications for colchicine treatment
  13. Use of systemic antimicrobial therapy within the previous 30 days or active infection
  14. History of respiratory illness that, in the opinion of a physician investigator, may increase the risk of pneumonia
  15. Surgery within the previous 30 days or surgery planned to occur within the expected study period
  16. Current or receipt of treatment for malignancy within the previous 1 year
  17. Frailty or life-expectancy shortened by comorbidity such as cancer that would increase the participant's risk in the opinion of a physician investigator
  18. \< 2,000 cells/mm3
  19. count \< 50,000 cells/mm3
  20. Concomitant use of a P-gp inhibitor (e.g., cyclosporine, ranolazine, digoxin) and/or moderate-strong inhibitor (e.g., clarithromycin, indinavir, itraconazole, ritonavir, nefazodone, diltiazem, verapamil, grapefruit juice, fluconazole)
  21. Medications that may cause myopathy or rhabdomyolysis (i.e., simvastatin, gemfibrozil, fenofibrate) , a creatine kinase level after the run-in period that exceeds the laboratory reference range (if baseline was below the upper limit) or that increases by 50% or more from pre- to post-run-in
  22. Moderate-severe hepatic disease ( B or C)
  23. Pregnant or unwilling/unable to assure appropriate
  24. Breastfeeding
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Colchicine

    Colchicine 0.3 mg once daily

    Drug: Colchicine

  • Placebo comparator
    Placebo

    Placebo once daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Between-group change in left ventricular global longitudinal strain

    Assessed using transthoracic echocardiography

    Time frame: 4 weeks

Secondary outcomes

  1. Between-group change in left ventricular systolic and diastolic function

    Assessed using transthoracic echocardiography

    Time frame: 4 weeks

  2. Between-group change in left ventricular volumes

    Assessed using transthoracic echocardiography

    Time frame: 4 weeks

  3. Between-group change in left ventricular size

    Assessed using transthoracic echocardiography

    Time frame: 4 weeks

  4. Between-group change in systemic inflammation

    Assessed using C-reactive protein

    Time frame: 4 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2021 to primary completion in Nov 2026, 60 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2020
First posted
Aug 5, 2020
StartActual
Nov 1, 2021
Primary completionActual
Nov 13, 2026was Jul 2026
CompletionActual
Nov 13, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Funding
changed Nov 18, 2026
Primary completion
Jul 31, 2026→Nov 13, 2026 (actual)
Nov 18, 2026
Study completion
Nov 11, 2026→Nov 13, 2026 (actual)
Nov 18, 2026
Enrollment
20 (estimated)→4 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Terminated
    Why stopped Funding
    Primary completion Jul 31, 2026→Nov 13, 2026 (now actual)
    Study completion Nov 11, 2026→Nov 13, 2026 (now actual)
    Enrollment 20 (estimated)→4 (actual)
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04500665
Responsible party
Leo F. Buckley, PharmD (Clinical Pharmacy Specialist, Brigham and Women's Hospital) — Principal investigator
First posted
Aug 5, 2020
Start date
Nov 1, 2021
Primary completion
Nov 13, 2026
Completion
Nov 13, 2026
Last update
Nov 18, 2026

Study contacts

Leo F Buckley, PharmD MPH
principal investigator · Brigham and Women's Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion